Understanding how WNT4 signaling is dysregulated, by estrogen and genetic polymorphism in ILC vs. gynecologic cancers, offers new opportunities for defining tumor biology, precision therapeutics, and personalized cancer risk assessment. This evidence concerns the gene WNT4 and neoplasm.